vecuronium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| neuromuscular blocking agents with rigid structure | 2811 | 50700-72-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 20 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.16 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.25 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.40 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 30, 1984 | FDA | ORGANON USA INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03AC03 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Other quaternary ammonium compounds |
| FDA PE | N0000175732 | Neuromuscular Nondepolarizing Blockade |
| FDA EPC | N0000175720 | Nondepolarizing Neuromuscular Blocker |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D009466 | Neuromuscular Blocking Agents |
| MeSH PA | D003473 | Neuromuscular Nondepolarizing Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018733 | Nicotinic Antagonists |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| CHEBI has role | CHEBI:48878 | nicotinic antagonist |
| CHEBI has role | CHEBI:51372 | neuromuscular agent |
| CHEBI has role | CHEBI:51371 | muscle relaxant |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Muscle relaxation, function | indication | 11977004 | |
| General anesthesia | indication | 50697003 | |
| Skeletal Muscle Relaxation for Endotracheal Intubation | indication | ||
| Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
| Obstruction of bile duct | contraindication | 30144000 | |
| Eaton-Lambert syndrome | contraindication | 56989000 | DOID:0050214 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Disorder of electrolytes | contraindication | 237840007 | |
| Morbid obesity | contraindication | 238136002 | DOID:11981 |
| Neuromyopathy | contraindication | 255522009 | DOID:440 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.58 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Acetylcholine receptor | Ion channel | ANTAGONIST | IC50 | 7.82 | WOMBAT-PK | CHEMBL | |||
| Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | WOMBAT-PK | |||||||
| Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | WOMBAT-PK | |||||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 5.46 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.60 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.72 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | WOMBAT-PK | |||||||
| Acetylcholine receptor; alpha1/beta1/delta/gamma | Ion channel | IC50 | 7.09 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018512 | VUID |
| N0000146834 | NUI |
| C0042435 | UMLSCUI |
| D00767 | KEGG_DRUG |
| 7E4PHP5N1D | UNII |
| 5100 | INN_ID |
| 86085000 | SNOMEDCT_US |
| 4019968 | VANDF |
| 013413 | NDDF |
| 7979 | MMSL |
| 71535 | RXNORM |
| 372883002 | SNOMEDCT_US |
| d00399 | MMSL |
| CHEMBL1200629 | ChEMBL_ID |
| DB01339 | DRUGBANK_ID |
| CHEBI:9940 | CHEBI |
| CHEMBL1201219 | ChEMBL_ID |
| D014673 | MESH_DESCRIPTOR_UI |
| 39765 | PUBCHEM_CID |
| 4002 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9232 | INJECTION, POWDER, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9234 | INJECTION, POWDER, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1632 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1634 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-2914 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-2925 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23360-160 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
| vecuronium bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47335-931 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |
| vecuronium bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47335-932 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |
| VECURONIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1475 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
| VECURONIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55150-235 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 12 sections |
| VECURONIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55150-236 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-781 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-782 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
| VECURONIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-438 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
| VECURONIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-475 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 13 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68083-139 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |
| Vecuronium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68083-140 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | ANDA | 12 sections |